Prostate Cancer
Conditions
Keywords
Astatine (At-211), Targeted alpha therapy, PSMA (Prostate Specific Membrane Antigen)
Brief summary
PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II.
Detailed description
PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II. PSW-1025 (\[At-211\]PSMA-5) is an alpha-ray-emitting drug labeled with Astatine (At-211) that targets PSMA (Prostate Specific Membrane Antigen).
Interventions
DRUGPSW-1025
PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)
Sponsors
Osaka University
Japan Agency for Medical Research and Development
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with progressive castration-resistant prostate cancer who meet the following conditions (1) and (2) (1) Patients with progressive increase of serum Prostate-Specific Antigen (PSA) (\>=2ng/mL, three consecutive increases at least one week apart, and two increases of more than 50% from the lowest value), or with the tumor growth or appearance of new lesions detected by imaging studies (2) Patients with the serum testosterone at castration level (\< 50ng/dL) 2. Patients who meet the following conditions (1) and (2), resistant to standard treatment or not indicated for the generally approved standard treatments (1) Patients who have received at least one of the following treatments * Inhibitors of androgen receptor signaling (enzalutamide, apalutamide, dalortamide, etc.) * Inhibitors of Cytochrome P450 17 (CYP 17) (abiraterone acetate) (2) Patients previously treated with the taxane-based chemotherapy (docetaxel or cabazitaxel) or not adapted for the taxane-based chemotherapy (including refusal cases)\* \* Targeting for the patients who have received cabazitaxel therapy after docetaxel therapy, or patients for whom cabazitaxel therapy was not indicated (including refusal cases) after docetaxel therapy, or patients for whom both docetaxel therapy and cabazitaxel therapy were not indicated (including refusal cases) 3. Patients aged 18 years or older at the time of consent acquisition 4. Patients with stable general condition with PS (Performance status) of 0 to 2 in ECOG (Eastern Cooperative Oncology Group) 5. Patients who can be expected to survive for 6 months or more, judging from clinical symptoms and medical examination findings 6. Patients without or with controlled symptomatic brain metastases 7. Patients with no clinically significant abnormal findings in electrocardiogram, respiratory rate, and blood oxygen saturation within 30 days before the enrollment 8. Patients whose laboratory values within 30 days before the enrollment are within the range specified in the protocol 9. Patients who can use appropriate contraception during the clinical trial period according to the protocol 10. Patients who thoroughly listened to the explanation of the clinical trial, agreed to the various study procedures outlined in the clinical trial protocol and signed the consent document
Exclusion criteria
1. Patients who received systemic antitumor therapy (e.g. chemotherapy, immunotherapy, biologic therapy such as monoclonal antibodies, excluding androgen receptor signaling inhibitors) within 4 weeks before enrollment 2. Patients who received radium chloride (Radium, 223Ra) or 177Lu (Lutetium)-PSMA-617 within 6 months before registration 3. Patients currently receiving treatment with other cytotoxic chemotherapy, immunotherapy, radioligand therapy, poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, AKT inhibitors 4. Patients with active double cancer (simultaneous double cancer and ectopic double cancer with a disease-free period of 5 years or less) 5. Patients who received other investigational drugs within 5 weeks prior to enrollment 6. Patients with uncontrollable active infections 7. Hepatitis B surface antigen positive, Hepatitis C Virus antibody positive (patients with HCV-RNA level below the limit of detection can be registered) or Human Immunodeficiency Virus antibody positive patients 8. Patients with mental illness or psychiatric symptoms who are judged to be difficult to participate in clinical trials 9. Other patients who are judged to be inappropriate by the investigator, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment-related adverse events as assessed by CTCAE v5.0 | until 6 months after administration |
| Dose Limiting Toxicity | within 4 weeks after single administration |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events and their details | until 6 months after administration |
| Blood pressure (mmHg) and heart rate (bpm) | until 6 months after administration |
| Symptoms of the participants | until 6 months after administration |
| Hematological tests (blood cell counts) | until 6 months after administration |
| Urine tests (occult blood and urine protein) | until 6 months after administration |
| Electrocorticogram | until 6 months after administration |
| Prostate-Specific Antigen (PSA) (ng/ml) | until 6 months after administration |
| Tumor size on CT (mm) | until 6 months after administration |
| Excretion rates in urine, feces, and breath (%injected dose) | until 24 hours after administration |
| Absorbed doses in major organs (Gy) | until 24 hours after administration |
Countries
Japan
Outcome results
None listed